Saturday, July 5, 2025 7/5/2025

Modifying the extracellular matrix to prevent dry eye disease and age-related Meibomian gland dysfunction (ARMGD)

Award Number: R01EY033024
ORGANIZATION: NATIONAL EYE INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2022
PERIOD OF PERFORMANCE END DATE: 04/30/2026

Group Awards By:

View Award Description

Modifying the extracellular matrix to prevent dry eye disease and age-related Meibomian gland dysfunction (ARMGD) - Project summary The prevalence of dry eye disease (DED) ranges from ~5 to 50% of the general population with an estimated US$ 3.8 billion dollars in associated medical costs. Symptoms of DED include pain, fatigued and/or sore eyes, photophobia and blurred vision, which lead to a decrease in productivity and reduce the quality of life. Unfortunately, treatment options for DED are limited. Clinical studies suggest 85% of overall DED cases are caused by Meibomian gland dysfunction (MGD). As humans and mice age, their Meibomian glands (MGs) undergo age-related changes, including decreased acinar basal cell proliferation and atrophy, and these changes result in age related-MGD (ARMGD). The precise cause of ARMGD remains elusive, which makes the development of therapies extremely challenging. Hyaluronan (HA) is a major extracellular component that interacts and binds to a myriad of molecules forming complex macromolecules which regulate major physiological functions, such as development and stem cell specification. Our recently published work shows that compound HA synthase (Has)-1 and -3 null mice, namely Has1-/-;Has3-/- mice, have enlarged MGs when compared to age matched wild-type (wt) mice. Our preliminary data show that the MGs of Has1-/-;Has3-/- mice continue to increase in size throughout life, and, interestingly, these mice do not develop ARMGD. At 1 year of age, Has1-/-;Has3-/- mice have a striking 4-fold increase in MG volume and an overall 10-fold increase in lipid production, compared to age matched wt mice. We hypothesize that the increase in HA expression in and around the MGs of Has1-/-;Has3-/- mice is capable of maintaining viable progenitor cells as they age, which in turn prevents ARMGD. Specific aim 1 of this proposal will characterize the extracellular matrix in the MGs of wt and Has1-/-;Has3-/- mice with a focus on the composition of the HA matrix. Specific aim 2 of this proposal will analyze the distribution of MG progenitor and proliferating cells in order to identify how the MGs of Has1- /-;Has3-/- mice enlarge over time. This aim will also characterize the lipid composition of the meibum, and verify whether enlarged glands can prevent DED. Importantly, although Has1-/-;Has3-/- mice lack two isoforms of the enzyme responsible for HA biosynthesis, they up-regulate the third isoform (Has2), and, in turn, present a significant increase in HA expression in and around MGs when compared to wt mice. Therefore, we also hypothesize that increasing Has2 expression and HA bioavailability within MGs could prevent ARMGD in aged wt mice. Specific aim 3 will test whether Has2 overexpression and FDA approved HA-based treatment regimens to increase the bioavailability of HA within tarsal plates and MGs can prevent ARMGD in wt mice.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $387,500 )
2025	2025	UNIVERSITY OF HOUSTON SYSTEM	4300 MARTIN LUTHER KING BLVD	HOUSTON	TX	77204	HARRIS	USA	Vision Research	000	4	4/4/2025	NON-COMPETING CONTINUATION	$387,500
														Subtotal = $387,500

Issue Date FY: 2024 ( Subtotal = $387,500 )
2024	2024	UNIVERSITY OF HOUSTON SYSTEM	4300 MARTIN LUTHER KING BLVD	HOUSTON	TX	77204	HARRIS	USA	Vision Research	000	3	8/2/2024	NON-COMPETING CONTINUATION	$387,500
														Subtotal = $387,500

Issue Date FY: 2023 ( Subtotal = $401,864 )
2023	2023	UNIVERSITY OF HOUSTON SYSTEM	4300 MARTIN LUTHER KING BLVD	HOUSTON	TX	77204	HARRIS	USA	Vision Research	000	2	5/4/2023	NON-COMPETING CONTINUATION	$401,864
														Subtotal = $401,864

Issue Date FY: 2022 ( Subtotal = $387,500 )
2022	2022	UNIVERSITY OF HOUSTON SYSTEM	4800 W CALHOUN ST STE 316	HOUSTON	TX	77004	HARRIS	USA	Vision Research	000	1	4/22/2022	NEW	$387,500
														Subtotal = $387,500

Grand Total All Awards = $1,564,364

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Modifying the extracellular matrix to prevent dry eye disease and age-related Meibomian gland dysfunction (ARMGD)

Award Number: R01EY033024

ORGANIZATION: NATIONAL EYE INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2022

PERIOD OF PERFORMANCE END DATE: 04/30/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer